AT2R autoantibodies block Angiotensin II and AT1R autoantibody-induced vasoconstriction

Hypertension

Volumn 66, Issue 4, 2015, Pages 830-835

  Liles, Campbell ^a   Li, Hongliang ^a   Veitla, Vineet ^a   Liles, Jonathan T ^a   Murphy, Taylor A ^a   Cunningham, Madeleine W ^b   Yu, Xichun ^a   Kem, David C ^a,c  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

angiotensin II type 1 receptor; angiotensin II type 2 receptor; hypertension; rabbit; vasoconstriction

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN TYPE 1 RECEPTOR ACTIVATING AUTOANTIBODY; ANGIOTENSIN TYPE 2 RECEPTOR ACTIVATING AUTOANTIBODY; AUTOANTIBODY; EPITOPE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VASODILATOR AGENT; BLOCKING ANTIBODY;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTERIOLE; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BLOOD VESSEL DIAMETER; BLOOD VESSEL FUNCTION; CONTROLLED STUDY; CROSS REACTION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REPRESSION; EXPERIMENTAL RABBIT; GENETIC TRANSFECTION; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; MEAN ARTERIAL PRESSURE; MUSCLE CONTRACTILITY; NONHUMAN; OPTICAL DENSITY; PEPTIDE SYNTHESIS; PRESSOR RESPONSE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; VACCINATION; VASOCONSTRICTION; VASODILATATION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; RABBIT;

ANGIOTENSIN II; ANIMALS; ANTIBODIES, BLOCKING; ARTERIOLES; AUTOANTIBODIES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYPERTENSION; MALE; RABBITS; RATS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; VASOCONSTRICTION;

EID: 84941236707     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.05428     Document Type: Article

References (21)

1. Carey RM, Angiotensin type-2 receptors and cardiovascular function: are angiotensin type-2 receptors protective? Curr Opin Cardiol 2005 20 264 269
2. Savoia C, D'Agostino M, Lauri F, Volpe M, Angiotensin type 2 receptor in hypertensive cardiovascular disease. Curr Opin Nephrol Hypertens 2011 20 125 132. doi: 10.1097/MNH.0b013e3283437fcd
3. Padia SH, Carey RM, AT2 receptors: beneficial counter-regulatory role in cardiovascular and renal function. Pflugers Arch 2013 465 99 110. doi: 10.1007/s00424-012-1146-3
4. Jones ES, Vinh A, McCarthy CA, Gaspari TA, Widdop RE, AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther 2008 120 292 316. doi: 10.1016/j.pharmthera.2008.08.009
5. Wallukat G, Schimke I, Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases. Semin Immunopathol 2014 36 351 363. doi: 10.1007/s00281-014-0425-9
6. Dragun D, Philippe A, Catar R, Hegner B, Autoimmune mediated G-protein receptor activation in cardiovascular and renal pathologies. Thromb Haemost 2009 101 643 648
7. Xia Y, Kellems RE, Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond. Circ Res 2013 113 78 87. doi: 10.1161/CIRCRESAHA.113.300752
8. LaMarca B, Wallace K, Granger J, Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia. Curr Opin Pharmacol 2011 11 175 179. doi: 10.1016/j.coph.2011.01.003
9. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jüpner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC, Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999 103 945 952. doi: 10.1172/JCI4106
10. Fu ML, Herlitz H, Schulze W, Wallukat G, Micke P, Eftekhari P, Sjögren KG, Hjalmarson A, Müller-Esterl W, Hoebeke J, Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens 2000 18 945 953
11. Liao YH, Wei YM, Wang M, Wang ZH, Yuan HT, Cheng LX, Autoantibodies against AT1-receptor and alpha1-Adrenergic receptor in patients with hypertension. Hypertens Res 2002 25 641 646
12. Dragun D, Müller DN, Bräsen JH, Angiotensin II type 1-receptor activating antibodies in renal-Allograft rejection. N Engl J Med 2005 352 558 569. doi: 10.1056/NEJMoa035717
13. Rossitto G, Regolisti G, Rossi E, Negro A, Nicoli D, Casali B, Toniato A, Caroccia B, Seccia TM, Walther T, Rossi GP, Elevation of angiotensin-II type-1-receptor autoantibodies titer in primary aldosteronism as a result of aldosterone-producing adenoma. Hypertension 2013 61 526 533. doi: 10.1161/HYPERTENSIONAHA.112.202945
14. Kem DC, Li H, Velarde-Miranda C, Liles C, Vanderlinde-Wood M, Galloway A, Khan M, Zillner C, Benbrook A, Rao V, Gomez-Sanchez CE, Cunningham MW, Yu X, Autoimmune mechanisms activating the angiotensin AT1 receptor in 'primary' aldosteronism. J Clin Endocrinol Metab 2014 99 1790 1797. doi: 10.1210/jc.2013-3282
15. Li H, Yu X, Cicala MV, Mantero F, Benbrook A, Veitla V, Cunningham MW, Kem DC, Prevalence of angiotensin II type 1 receptor (AT1R)-Activating autoantibodies in primary aldosteronism. J Am Soc Hypertens 2015 9 15 20. doi: 10.1016/j.jash.2014.10.009
16. Li H, Kem DC, Zhang L, Huang B, Liles C, Benbrook A, Gali H, Veitla V, Scherlag BJ, Cunningham MW, Yu X, Novel retro-inverso peptide inhibitor reverses angiotensin receptor autoantibody-induced hypertension in the rabbit. Hypertension 2015 65 793 799. doi: 10.1161/HYPERTENSIONAHA.114.05037
17. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr, Montori VM, Endocrine Society Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008 93 3266 3281. doi: 10.1210/jc.2008-0104
18. Li H, Zuccolo J, Kem DC, Zillner C, Lee J, Smith K, James JA, Cunningham MW, Yu X, Implications of a vasodilatory human monoclonal autoantibody in postural hypotension. J Biol Chem 2013 288 30734 30741. doi: 10.1074/jbc.M113.477869
19. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T, International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000 52 415 472
20. Wan Y, Wallinder C, Plouffe B, Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem 2004 47 5995 6008. doi: 10.1021/jm049715t
21. Foulquier S, Steckelings UM, Unger T, Impact of the AT(2) receptor agonist C21 on blood pressure and beyond. Curr Hypertens Rep 2012 14 403 409. doi: 10.1007/s11906-012-0291-6